FibroGen (FGEN) Tops Q3 EPS by 55c; Reports Cash and Cash Equivalents of $665.0M

FibroGen (NASDAQ: FGEN) reported Q3 EPS of $0.54, $0.55 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $156 million versus the consensus estimate of $143.46 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Benchmark Reiterates Buy Rating on IMAX Corporation (IMAX), Highlights 'The Odyssey' Potential
• MakeMyTrip (MMYT) PT Raised to $84 at Goldman Sachs